Establishment of induced pluripotent stem cells from human neonatal tissues.
Following the success in establishing human induced pluripotent stem (iPS) cells, research into various applications of the cells derived from human iPS cells has begun in earnest. The use of iPS cell-derived cells in clinical therapies is one of the most exciting of the possible applications. However, the risk of tumorigenicity is the biggest potential obstacle to use iPS cell derivatives in the clinic. It should be noted that the human cells used to generate iPS cell lines may have acquired genetic mutations and these might influence the tumorigenicity of the cells. In particular, the cells of older people have a higher risk of genetic mutations than those of younger people. Here, we show that iPS cells could be derived from short-term cultures of neonatal tissues. The established human iPS cells expressed various markers of undifferentiated cells and formed teratoma in immunodeficient mice. The human iPS cells derived from neonatal tissues may represent a clinical material possessing less tumorigenicity.
Cell Engineering Division, and Subteam for Cell Fate Manipulation, RIKEN BioResource Center, Tsukuba, Ibaraki, Japan.
Tsuyoshi
T
Fujioka
Natsumi
N
Shimizu
Kaori
K
Yoshino
Hiroyuki
H
Miyoshi
Yukio
Y
Nakamura
D000818:Animals; D002460:Cell Line; D002471:Cell Transformation, Neoplastic; D005321:Extraembryonic Membranes / Q000166:cytology*; D006801:Humans; D007231:Infant, Newborn; D007621:Karyotyping; D051379:Mice; D018895:Microsatellite Repeats; D009368:Neoplasm Transplantation; D039904:Pluripotent Stem Cells / Q000166:cytology / Q000473:pathology; D013724:Teratoma / Q000473:pathology; D014470:Umbilical Cord / Q000166:cytology*